In this video, Motley Fool health-care analyst David Williamson discusses what investors should look for in Eli Lilly's upcoming earnings report, and what the big pharma has in store for 2013.
Over the next two years, Eli Lilly will see nearly $0.40 of every $1.00 in sales exposed to generic competition. How does the company plan to respond to this huge patent cliff? Better yet, what does this mean for investors? In a brand-new premium report on Eli Lilly, The Motley Fool's top pharmaceuticals analyst delves into everything investors need to know about the stock today. Simply click here now to claim your copy.